Entrada Therapeutics (TRDA) Return on Capital Employed (2021 - 2026)

Entrada Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 52.9% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 5374.0% year-over-year to 52.9%; the TTM figure through Mar 2026 stood at 52.9% (down 5374.0% YoY), while the FY2025 annual figure was 36.94%, down 4720.0% from the prior year.
• Return on Capital Employed was 52.9% for Q1 2026 at Entrada Therapeutics, down from 42.6% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 20.29% in Q2 2024 to a low of 52.9% in Q1 2026.
• Historically, Return on Capital Employed has averaged 17.07% across 5 years, with a median of 21.47% in 2025.
• The sharpest annual moves came in 2024 and 2026: Return on Capital Employed jumped 4491 bps in 2024, then plunged 5374 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 40.3% in 2022, then soared by 98 bps to 0.99% in 2023, then soared by 1045 bps to 9.38% in 2024, then slumped by 554 bps to 42.6% in 2025, then fell by 24 bps to 52.9% in 2026.
• The last three Return on Capital Employed figures came in at 52.9% (Q1 2026), 42.6% (Q4 2025), and 29.88% (Q3 2025), per Business Quant data.